Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Galenica AG ( (CH:GALE) ).
Shareholders of Galenica AG approved all board proposals at the company’s ninth ordinary annual general meeting, with 75.2% of voting share capital represented and the entire board, including chairman Markus R. Neuhaus, confirmed for another term. The strong backing underscores investor confidence in Galenica’s strategic direction and its role in shaping Switzerland’s healthcare system.
The meeting also endorsed an 8.7% increase in the dividend to CHF 2.50 per share for the 2025 financial year, implying a payout of CHF 125 million and signaling the group’s commitment to a sustainable, shareholder-friendly distribution policy. In addition, shareholders approved the introduction of a capital band, enhancing Galenica’s financial and strategic flexibility by allowing the board to adjust share capital within a defined range, and cleared the board and executive committee for the year while authorizing future compensation limits.
The most recent analyst rating on (CH:GALE) stock is a Sell with a CHF85.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.
More about Galenica AG
Galenica AG is a Swiss healthcare group listed on SIX Swiss Exchange, operating a nationwide network of pharmacies, pharmaceutical logistics, home care services, and health-related products. With more than 8,000 employees, the company focuses on providing integrated, efficient and personalized solutions for customers and patients across the Swiss healthcare market.
Average Trading Volume: 96,401
Technical Sentiment Signal: Buy
Current Market Cap: CHF4.45B
For an in-depth examination of GALE stock, go to TipRanks’ Overview page.